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Hypoxia attenuates inflammation-induced hepcidin
synthesis during experimental human endotoxemia
Hepcidin is the central mediator of iron homeostasis
that limits iron availability in the extracellular compart-
ment and causes iron-restricted erythropoiesis.
Inflammation is a strong hepcidin inducer, which can
lead to anemia of inflammation, whereas hypoxia can
suppress hepcidin synthesis. Inflammation, hypoxia and
anemia are often encountered in critically ill patients. In
the present study, we determined the effects of hypoxia
on parameters of iron regulation and homeostasis in
humans in vivo during systemic inflammation induced by
endotoxin administration. We report that systemic
inflammation results in increased plasma hepcidin levels
and a subsequent decrease in serum iron levels. Hypoxia
attenuates these endotoxemia-induced effects on hep-
cidin and iron parameters, likely through increased syn-
thesis of erythropoietin and erythroferrone. 
Hepcidin binds to the iron exporter ferroportin
expressed on macrophages and duodenal enterocytes,
leading to its internalization and degradation, thereby
reducing iron export into the extracellular compartment.1
Hepcidin regulation is mainly driven by body iron status
and systemic inflammation, which is a major hepcidin
inducer. The redistribution of iron into iron-storing cells
as a result of increased hepcidin synthesis during infec-
tion is considered a part of the innate immune response
against extracellular proliferating pathogens, as iron is a
vital nutrient for microbial growth and replication. In
contrast to inflammation, hypoxia is a strong hepcidin
suppressor.2 Hypoxia promotes increased transport of
iron from storage sites to facilitate erythropoiesis in the
bone marrow.3,4 Erythropoiesis is induced by erythropoi-
etin, which increases the production of erythroferrone, a
known suppressor of hepcidin synthesis.5 The great
majority of critically ill patients suffer from inflammatory
conditions, such as sepsis, major surgery and trauma, and
also develop anemia.6 This so-called “anemia of inflam-
mation” is associated with worse outcome.7,8 As such,
efforts have been made to develop therapies that inhibit
hepcidin synthesis or mitigate its downstream effects.9
Besides causing anemia, pronounced systemic inflamma-
tion often leads to concurrent tissue hypoxia in critically
ill patients due to respiratory dysfunction, hemodynamic
instability, microthrombi, and tissue edema. Therefore,
there may be some interplay between both phenomena
with regard to hepcidin synthesis and iron homeostasis,
although this has not yet been studied in humans. Here,
we investigated the effect of hypoxia on erythropoietin,
erythroferrone and hepcidin synthesis, and iron home-
ostasis parameters in healthy volunteers during experi-
mental endotoxemia, a standardized controlled model of
systemic inflammation in humans in vivo.
Data were obtained from subjects participating in an
open-label, randomized, parallel group intervention
study (clinicaltrials.gov identifier: 01978158) aimed at
investigating the effects of modulation of oxygen status
during systemic inflammation on immunological (prima-
ry outcome) and many other parameters, including
hemodynamic effects, coagulation, the endocrine
response, and renal function (complete list provided at
https://clinicaltrials.gov/ct2/show/NCT01978158). The pri-
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Figure 1. Parameters of iron regulation and
homeostasis. (A) Plasma erythropoietin. (B)
Plasma erythroferrone. (C) Plasma hepcidin.
(D) Serum iron. (E) Total iron binding capacity
(TIBC). (F) Hemoglobin. The gray box indicates
the period of hypoxic exposure; endotoxin
was administered at 0 hours. Data are
expressed as Mean±Standard Deviation.
Between-group differences over time (base-
line to 8 hours post-endotoxin administration)
were analyzed with repeated measures two-
way ANOVA (interaction term displayed in
each panel). **P<0.01, unpaired Student 
t-test. 
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mary outcomes have been published elsewhere and are
freely accessible.10 The trial was approved by the local
ethics committee and carried out according to Good
Clinical Practice standards and the Declaration of
Helsinki, including current revisions. The Methods used
have been published in detail elsewhere.10 Briefly, after
obtaining written informed consent, subjects were
declared eligible based on a screening procedure that
included a full medical history, physical examination,
electrocardiogram and routine laboratory tests. Twenty
male non-smoking subjects, aged between 18 and 35
years, were randomized to receive either hypoxia (n=10)
or normoxia (n=10) during experimental endotoxemia.
Hypoxic exposure [peripheral oxygen saturation (SaO2)
80-85%] started one hour (h) before, and continued until
2.5 h after endotoxin administration, and was achieved
by feeding a nitrogen/medical air mixture into an airtight
respiratory helmet (CaStar, StarMed, Italy). Normoxic
subjects were fitted with the same respiratory helmet fed
with medical air (FiO2 21%). Purified standard reference
Escherichia coli O:113 LPS (Clinical Center Reference
Endotoxin, National Institutes of Health, Bethesda, MD,
USA) was administered intravenously at a dose of 2
ng/kg body weight to elicit a systemic inflammatory
response. Blood samples were obtained from an arterial
catheter (up to 8 h after endotoxin administration) or
venipuncture (at 24 h post endotoxin). Plasma erythro-
poietin and erythroferrone concentrations were deter-
mined by ELISA (eBioscience, Vienna, Austria, and
MyBioSource, San Diego, CA, USA, respectively). Plasma
hepcidin levels were measured using a specifically
designed competitive ELISA11 with a lower limit of detec-
tion of 0.42 nmol/L; none of the measured concentra-
tions fell below this lower limit. Serum iron and transfer-
rin were determined using routine analytical methods
(Architect c16000, Abbott Diagnostics, Lake Forest,
USA), as was hemoglobin (Sysmex XE 5000, Sysmex
Corp., Kobe, Japan). Total iron binding capacity (TIBC)
was calculated as: TIBC (µmol/L)=25 (µmol/g) x transfer-
rin (g/L). Transferrin saturation (TSAT) was calculated as:
TSAT (%)serum iron [(µmol/L)/TIBC (µmol/L)] x 100. 
Plasma cytokine levels were determined by Luminex
assay (Merck Millipore, Billerica, MA, USA).
Data are expressed as Mean±Standard Deviation, and
between-group differences over time (baseline to eight
hours after endotoxin administration) were analyzed
with repeated measures two-way analysis of variance
(ANOVA, interaction term). Differences between groups
at baseline and 24 h after endotoxin administration were
evaluated using unpaired Student t-tests. P<0.05 was
considered statistically significant.
As detailed elsewhere,10 an SaO2 of 80-85% was
achieved using a mean FiO2 of 11.4±0.7% in the hypoxia
group. All subjects experienced typical flu-like symptoms
that peaked 90 minutes (min) after endotoxin administra-
tion and subsided within a few hours. Hypoxia resulted
in increased plasma erythropoietin concentrations from
90 min after endotoxin administration onwards (Figure
1A). In normoxic subjects, erythropoietin levels were
increased only at 24 hours (h) post endotoxin administra-
tion, and at that time point, concentrations were similar
to those observed in subjects who had previously been
exposed to hypoxia. In both groups, circulating erythro-
ferrone and hepcidin levels increased over time (Figure 1B
and C). Hypoxia augmented the endotoxemia-induced
increase in erythroferrone and attenuated the increase in
hepcidin levels, of which the latter effect manifested later
(6 h after endotoxin administration). Baseline serum iron
concentrations were comparable in both groups (21±7.1
vs. 17.4±5.9 µmol/L in the hypoxia and normoxia groups,
respectively; P=0.23). In line with previous work,12,13
endotoxemia resulted in an initial increase in serum iron,
peaking three hours after endotoxin administration, fol-
lowed by a decrease to below baseline values that was
most pronounced eight hours post-endotoxin administra-
tions (Figure 1D). Transferrin saturation showed almost
the exact same profile as serum iron concentrations with
no differences between the treatment groups up till eight
hours post-endotoxin administration (data not shown).
However, 24 hours after endotoxin administration, sig-
nificantly higher levels of serum iron (16.8±4.1 vs.
10.6±3.4 µmol/L; P=0.002) and transferrin saturation
(28.8±8.5 vs. 17.8±5.5; P=0.003) were observed in the
hypoxia group compared with the normoxia group. No
clear effects of either endotoxemia or hypoxia were
observed on TIBC (Figure 1E). Baseline hemoglobin levels
were higher in the hypoxia group (149.4±6.6 vs.
143.3±5.4 g/L; P=0.04), and an initial decrease was
observed in both groups due to our prehydration proto-
col14 (Figure 1F). Furthermore, there was a significant dif-
ference in hemoglobin concentrations over time between
groups. Baseline hemoglobin levels did not correlate with
baseline or peak hepcidin levels, or with serum iron or
TSAT at baseline or t=24 hours in either group (all
P>0.10). Plasma cytokine levels markedly increased in all
subjects after endotoxin administration.10 Hypoxia result-
ed in a 2-fold increase in concentrations of the anti-
inflammatory cytokine interleukin (IL)-10, and a 30-50%
reduction in levels of pro-inflammatory cytokines tumor
necrosis factor alpha, IL-6 and IL-8.10 There were no sig-
nificant correlations between cytokine responses [area
under the concentration-time curve (AUC)] and peak or
AUC hepcidin concentrations (all P>0.10).
Taken together, our data demonstrate that exposure of
healthy volunteers to hypoxia during experimental endo-
toxemia enhances erythropoietin and erythroferrone
concentrations, and partially suppresses inflammation-
induced hepcidin synthesis. Furthermore, hypoxia miti-
gates the inflammation-induced decrease in serum iron
levels and transferrin saturation at later time points. 
Since its discovery in 2000, many regulatory pathways
concerning hepcidin synthesis have been discovered. The
main hepcidin-enhancing pathways are the BMP-SMAD
pathway, activated by high iron stores, and the JAK-
STAT3 pathway induced by inflammatory mediators
such as IL-6,15 which accounts for the phenomenon
known as anemia of inflammation.16,17 This occurs in
both chronic (e.g. autoimmune diseases) and acute (e.g.
sepsis) inflammatory conditions.18 Previous studies
revealed that hepcidin levels are increased in septic
patients, and that this is associated with the development
of anemia.18 Our data show that hypoxia can partially
reverse the effects of acute inflammation on hepcidin
synthesis and its downstream effects on serum iron levels
and transferrin saturation. 
Hypoxia has been described to suppress hepcidin syn-
thesis through various mechanisms, many of which
involve a group of transcription factors called hypoxia
inducible factors (HIF). Although HIF do not directly
affect hepcidin levels,19 HIF induction results in increased
erythropoietin production, in turn leading to increased
synthesis of erythroferrone, a known hepcidin suppres-
sor;5 this cascade was also observed in this study. An
alternative explanation for the observed change in hep-
cidin is that HIF induction also increases levels of furin, a
protease that cleaves hemojuvelin and thereby produces
soluble hemojuvelin, an inhibitor of the BMP-SMAD
pathway.20 The relevance of HIF for hepcidin regulation
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and for iron mobilization and utilization in vivo is sup-
ported by the notion that patients who use pharmacolog-
ical HIF-inducers (called prolylhydroxylase inhibitors) for
renal anemia present decreased hepcidin and ferritin lev-
els, and an increase in total iron binding capacity and
hemoglobin (e.g. for vadadustat21). Finally, hypoxia may
decrease hepatic hepcidin transcription via induction of
platelet derived growth factor-BB.22 Due to the nature of
this study, we cannot ascertain a cause-effect relationship
between hepcidin levels at six hours and iron levels at 24
hours. Nevertheless, a murine study has shown that
exogenously administered hepcidin affects iron levels for
up to 48 hours, long after hepcidin levels had returned to
baseline.23 Therefore, such a cause-effect relationship
may be present in humans as well. 
Interestingly, erythroferrone levels also increased in
normoxic subjects after endotoxin administration. This
increase was not preceded by enhanced concentrations
of erythropoietin, which is, to the best of our knowledge,
the only known inducer of erythroferrone synthesis.5
Therefore, it might be speculated that other inflamma-
tion-related mechanisms also induce erythroferrone syn-
thesis.
Worthy of mention is the fact that experimental human
endotoxemia is a relatively mild model of systemic
inflammation. As such, our results may not be directly
applicable to critically ill patients. In addition, long-term
effects of hypoxia on iron parameters remain to be deter-
mined, as we did not obtain blood samples from the
study subjects later than 24 hours after endotoxin admin-
istration. Finally, there were significant between-group
differences in baseline hemoglobin levels and in the
change in hemoglobin concentrations over time, which
can only be explained by an unbalanced randomization.
Although no relationships between baseline hemoglobin
level and peak levels of, or changes in hepcidin or iron
levels were identified, we cannot exclude this as a con-
founding factor.
In conclusion, we demonstrate that hypoxia augments
erythropoietin and erythroferrone levels, partially atten-
uates the inflammation-induced increase in hepcidin con-
centrations, and mitigates the decrease in serum iron lev-
els and transferrin saturation. These results may be of
special relevance to critically ill patients, in whom inflam-
mation and hypoxia often coincide. 
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